Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 78

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 78
---
 agreements between us and third parties are and will be valid and subsisting in the future                
 or until their expiry dates, and that we have complied with our contractual obligations under the license agreements; |

| • | all intellectual property capable of being commercialized that is or has been generated pursuant to collaboration 
 agreements between us and third parties will be or has been identified;                                           |

| • | all intellectual property generated pursuant to collaboration agreements and to which we have a contractual          
 entitlement or generated by employees has been lawfully assigned into our sole name (or to one of our subsidiaries); |

| • | in respect of all intellectual property generated pursuant to a collaboration agreement between us and                                 
 a third party to which we and that third party have a joint contractual entitlement, that such intellectual property has been lawfully 
 assigned into joint names and the rights between us and that third party are properly regulated by a co-ownership agreement; and       |

| • | beyond contractual warranties, the licensors of intellectual property to us or our affiliates own the                                  
 relevant patents and that those patents have not and will not be the subject of, or subject to, infringement, invalidity or revocation 
 actions.                                                                                                                               |

The steps we have taken to
protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our
intellectual property rights, both inside and outside of the United Kingdom and United States. The rights already granted under any of
our currently issued patents and those that may be granted under future issued patents may not provide us with the proprietary protection
or competitive advantages we are seeking. If we are unable to obtain and maintain patent protection for our technology and products, or
if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products
similar or superior to ours, and our ability to successfully commercialize our technology and products may be adversely affected.

With respect to patent rights,
we do not know whether any of the pending patent applications for any of our licensed compounds will result in the issuance of patents
that protect our technology or products, or which will effectively prevent others from commercializing competitive technologies and products.
Although we have a number of issued patents covering our technology, our pending applications cannot be enforced against third parties
practicing the technology claimed in such applications unless and until a patent issues from such applications. Further, the examination
process may require us to narrow the claims, which may limit the scope of patent protection that may be obtained. Because the